Table 1.
Clinical characteristics
| Category | ID | Sex | Age at onset (years) | Type | Duration (years) | GADA‐RIA (U/mL) | GADA‐ELISA (U/mL) | IA‐2A‐RIA | ZnT8A‐ELISA | TPOA | TgA |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GADA‐RIA(+)/ELISA(−) | SK8 | F | 32 | Acute | 35 | 2.4† | 1.8 | Negative | Negative | Positive | Positive |
| SK13 | F | 31 | Fulminant | 10 | 4.1† | 1.3 | Negative | Negative | Negative | Negative | |
| SK15 | M | 47 | SPIDDM | 12 | 25.2† | 1.6 | Negative | Negative | Negative | Negative | |
| OK78 | F | 40 | SPIDDM | 23 | 8.1† | 1.6 | Negative | Negative | Negative | Negative | |
| OK30 | F | 48 | SPIDDM | 14 | 4.3† | 1.3 | Negative | Negative | Negative | Negative | |
| GADA‐RIA(−)/ELISA(+) | SK1 | M | 39 | SPIDDM | 12 | 0.0 | 8.8† | Negative | Negative | Negative | Negative |
| SK18 | F | 57 | Acute | 19 | 1.4 | 55.4† | Negative | Negative | Positive | Negative | |
| SK25 | M | 50 | SPIDDM | 11 | 0.0 | 37.1† | Negative | Negative | Negative | Negative | |
| SK27 | M | 29 | SPIDDM | 36 | 0.0 | 10.7† | Negative | Negative | Negative | Negative | |
| SK30 | M | 86 | SPIDDM | 3 | 0.0 | 11.9† | Positive | Positive | Positive | Negative | |
| SK5 | F | 39 | SPIDDM | 26 | 0.0 | 11.7† | Negative | Negative | Negative | Negative | |
| OK61 | F | 30 | SPIDDM | 39 | 0.0 | 23.0† | Negative | Negative | Negative | Negative |
†
Autoantibody positive. Acute, acute‐onset type 1 diabetes; Fulminant, fulminant type 1 diabetes; GADA, glutamic acid decarboxylase antibody; IA‐2A, insulinoma‐associated antigen‐2 antibody; SPIDDM, slowly progressive type 1 diabetes; TgA, thyroglobulin antibody; TPOA, thyroid peroxidase antibody; ZnT8A, zinc transporter‐8 antibody.